Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Sequential Infusion of Anti-CD19 and Anti-BCMA Chimeric Antigen Receptor T-Cells: A Promising Treatment Strategy for Refractory Immune-Mediated Platelet Transfusion Refractoriness

Yunju Ma, Qingya Cui, Chunxiu Yang, Wei Cui, Mengyun Li, Zheng Li, Haiping Dai, Liqing Kang, Lei Yu, Zaixiang Tang, Jianxin Fu, Min Jiang, Depei Wu, Xiaowen Tang

Blood (2024) 144 (Supplement 1): 683.

https://doi.org/10.1182/blood-2024-209249

Published: 2024

Journal Articles

Safety and Efficacy of VA Combined with Modified BuCy Conditioning Regimen Followed By Allo-HSCT for High-Risk or Refractory/Relapsed Acute Lymphoblastic Leukemia : A Prospective, Single-Center, Single-Arm Clinical Trial

Xiaoqian Chen, Wei Cui, Qingya Cui, Zheng Li, Sifan Chen, Mengyun Li, Xuekai Li, Juan Chen, Yan Yu, Xin Zhang, Depei Wu, Xiaowen Tang

Blood (2024) 144 (Supplement 1): 270.

https://doi.org/10.1182/blood-2024-209163

Published: 2024

Journal Articles

Unleashing the Power of CD19 CAR-T in Relapsed AML: Findings from a Prospective Single-Center Clinical Trial

Jia Yin, Qingya Cui, Haiping Dai, Zheng Li, Liqing Kang, Wei Cui, Xiaopeng Tian, Xiaming Zhu, Lei Yu, Depei Wu, Xiaowen Tang

Blood (2024) 144 (Supplement 1): 4836.

https://doi.org/10.1182/blood-2024-207197

Published: 2024

Journal Articles

Comparing the Efficacy and Safety of VAC (Venetoclax, Azacitidine, Chidamide) and VA Regimens As Induction Therapy for Newly Diagnosed Patients with Immunophenotypically Mature Monocytic AML

Kai-Wen Tan, Shanshan Pei, Miao Wang, Lan Dai, Hao Zhang, Chun-Yan Chen, Zhen-Qi Huang, Hai-Ping Dai, Ying Wang, Miao Miao, Yue Han, Xiaowen Tang, Huiying Qiu, Suning Chen, Aining Sun, Depei Wu, Zheng Li, Sheng-Li Xue

Blood (2024) 144 (Supplement 1): 1507.

https://doi.org/10.1182/blood-2024-204762

Published: 2024

Journal Articles

Bird Regimen Followed By Anti-BCMA CAR T-Cell Immunotherapy As First-Line Therapy for Newly Diagnosed Multiple Myeloma: A Prospective, Single-Arm, Phase 3 Trial

Yue Zhou, Juan Chen, Qingya Cui, Haiping Dai, Zheng Li, Jia Yin, Wei Cui, Mengyun Li, Xuekai Li, Xin Zhang, Feiran Gong, Xiaming Zhu, Liqing Kang, Lei Yu, Depei Wu, Xiaowen Tang

Blood (2024) 144 (Supplement 1): 3384.

https://doi.org/10.1182/blood-2024-199119

Published: 2024

Journal Articles

Safety and Efficacy of Blinatumomab and Auto-HSCT “Sandwich” Strategy As Consolidation Therapy for Ph Negative B Cell Acute Lymphoblastic Leukemia

Chong-Sheng Qian, Zihao Wang, Lan Dai, Li Yao, Zhen Yao, HaiXia Zhou, Mingzhu Xu, Wenjie Gong, Zheng Li, Haiping Dai, Aining Sun, Depei Wu, Shengli Xue

Blood (2024) 144 (Supplement 1): 5878.

https://doi.org/10.1182/blood-2024-205115

Published: 2024

Journal Articles

VA Combined with Mbucy Conditioning Regimen Followed By Allo-HSCT Can Improve Survival of High-Risk AML Patients: A Prospective, Single-Center, Single-Arm Clinical Trial

Wei Cui, Xiaoqian Chen, Qingya Cui, Zheng Li, Sifan Chen, Mengyun Li, Xuekai Li, Juan Chen, Yan Yu, Depei Wu, Xiaowen Tang

Blood (2024) 144 (Supplement 1): 3493.

https://doi.org/10.1182/blood-2024-207083

Published: 2024

Journal Articles

Application of cfDNA-NGS Test in MRD Monitoring of Acute Leukemia Patients with CAR-T Cell Therapy

Juncheng Chen, Qingya Cui, Mengyun Li, Zheng Li, De-Pei Wu, Xiaowen Tang, Hongjie Shen

Blood (2023) 142 (Supplement 1): 2282.

https://doi.org/10.1182/blood-2023-186203

Published: 2023

Journal Articles

Venetoclax+Azacytidine Followed By Modified BuCy Conditioning Regimen for High Risk or Refractory/Relapsed Acute Lymphoblastic Leukemia and High Risk Myelodysplastic Syndromes

QI Tan, Zheng Li, Sifan Chen, Qingya Cui, Mengyun Li, Ye Zhao, Feng Chen, Depei Wu, Xiaowen Tang

Blood (2023) 142 (Supplement 1): 4909.

https://doi.org/10.1182/blood-2023-185976

Published: 2023

Journal Articles

Rituximab Improves Clinical Outcomes of CAR-T Therapy for r/r B-ALL Via Sensitizing Leukemia Cells to CAR-T-Mediated Cytotoxicity and Reducing CAR-T Exhaustion

Yangzi Li, Sining Liu, Qingya Cui, Lingling Liu, Zheng Li, Wei Cui, Mengyun Li, Xiaming Zhu, Liqing Kang, Lei Yu, Depei Wu, Xiaowen Tang

Blood (2023) 142 (Supplement 1): 6803.

https://doi.org/10.1182/blood-2023-184505

Published: 2023

Journal Articles

Efficacy and Safety of the Second CAR-T Therapy in Patients with Refractory/Relapsed Acute B-Cell Lymphoblastic Leukemia

Sining Liu, Qingya Cui, Zheng Li, Wei Cui, Mengyun Li, Huiying Qiu, Shengli Xue, Suning Chen, Zhengming Jin, Miao Miao, Yue Han, Ying Wang, Xiaming Zhu, Lei Yu, Depei Wu, Xiaowen Tang

Blood (2023) 142 (Supplement 1): 3491.

https://doi.org/10.1182/blood-2023-186718

Published: 2023

Journal Articles

Chidamide Combined with a Modified Bu-Cy Conditioning Regimen Improves Survival in Patients with T-Cell Acute Lymphoblastic Leukemia/Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Xuanqi Cao, Zheng Li, Yanming Zhang, Qingya Cui, Yunju Ma, Mengyun Li, Sifan Chen, Jia Yin, Wei Cui, Jia Chen, Aining Sun, Huiying Qiu, Suning Chen, Zhengming Jin, Xiaming Zhu, De-Pei Wu, Xiaowen Tang

Blood (2023) 142 (Supplement 1): 6959.

https://doi.org/10.1182/blood-2023-185258

Published: 2023

Journal Articles

Anti CD19 CART Therapy Following Allogenic Hematopoietic Stem Cell Transplantation Improved the Survival of Patients with BCR::ABL1 -like Acute Lymphoblastic Leukemia

Haiping Dai, Wei Cui, Hongjie Shen, Qian Wang, Jia Yin, Zheng Li, Depei Wu, Xiaowen Tang

Blood (2022) 140 (Supplement 1): 10345–10346.

https://doi.org/10.1182/blood-2022-166687

Published: 2022

Journal Articles

Disruption of dNTP homeostasis by ribonucleotide reductase hyperactivation overcomes AML differentiation blockade

Blood (2022) 139 (26): 3752–3770.

https://doi.org/10.1182/blood.2021015108

Published: 2022

Includes: Supplemental data

Journal Articles

Tandem CD19/CD22 Dual Targets CAR T-Cells Bridging Hematopoietic Stem Cells Transplantation Acquires Robust Remission for Relapsed and Refractory B Acute Lymphoblastic Leukemia Patients

Wei Cui, Xinyue Zhang, Haiping Dai, Qingya Cui, Jia Yin, Zheng Li, Lei Yu, Liqing Kang, Depei Wu, Xiaowen Tang

Blood (2021) 138 (Supplement 1): 1753.

https://doi.org/10.1182/blood-2021-152565

Published: 2021

Journal Articles

Tandem CD19/CD22 Dual Targets CAR-T Cells Therapy Obtains Superior CR Rate Than Single CD19 CAR-T Cells Infusion As Well As Sequential CD19 and CD22 CAR-T Cells Infusion for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Patients

Blood (2021) 138 (Supplement 1): 1755.

https://doi.org/10.1182/blood-2021-152927

Published: 2021

Journal Articles

Tandem CD19/CD22 Dual Targets CAR-T Cells Therapy Acquires Superior CR Rate Than CD19 CAR-T Cells: A Case Controlled Study

Wei Cui, Xinyue Zhang, Haiping Dai, Qingya Cui, Baoquan Song, Depei Wu, MDPhD, Xiaowen Tang, MD PhD, Jia Yin, Zheng Li

Blood (2020) 136 (Supplement 1): 44.

https://doi.org/10.1182/blood-2020-143474

Published: 2020

Journal Articles

Repurposing Nelarabine to Induce Differentiation of Acute Myeloid Leukemia

Hanying Wang, Xin He, MD, Feiteng Huang, MS, Haojie Dong, PhD, Wei Chen, PhD, Zheng Li, MS, Jie Sun, PhD, Yinghui Zhu, PhD, Lei Zhang, MD, Yuhui Wu, MD, Lifeng Feng, PhD, Jing Zhang, PhD, Samer Khaled, MD, Guido Marcucci, MD, David Sykes, MD PhD, Hongchuan Jin, MD PhD, Xian Wang, MD PhD, Ling Li, PhD

Blood (2020) 136 (Supplement 1): 26.

https://doi.org/10.1182/blood-2020-139922

Published: 2020

Journal Articles

CD38-Directed CAR-T Cell Therapy: A Novel Immunotherapy Strategy for Relapsed Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation

Xiaowen Tang, MD PhD, Depei Wu, MDPhD, Qingya Cui, Chongsheng Qian, Nan Xu, Liqing Kang, Haiping Dai, Baoquan Song, Wei Cui, Jia Yin, Zheng Li, Lei Yu, MD PhD

Blood (2020) 136 (Supplement 1): 34.

https://doi.org/10.1182/blood-2020-141602

Published: 2020

Journal Articles

Tandem CAR T Cells Targeting CD19 and CD22 Is a Safe and Highly Efficacious Treatment for Relapse/ Refractory ALL Patients

Xiaowen Tang, Liqing Kang, Wei Qi, Wei Cui, Haiping Dai, Zheng Li, Jia Yin, Changju Qu, PhD, Ting Xu, Xiaming Zhu, Lei Yu, MD PhD, Depei Wu, MD PhD

Blood (2019) 134 (Supplement_1): 1338.

https://doi.org/10.1182/blood-2019-127890

Published: 2019

NARROW

Sequential Infusion of Anti-CD19 and Anti-BCMA Chimeric Antigen Receptor T-Cells: A Promising Treatment Strategy for Refractory Immune-Mediated Platelet Transfusion Refractoriness

Safety and Efficacy of VA Combined with Modified BuCy Conditioning Regimen Followed By Allo-HSCT for High-Risk or Refractory/Relapsed Acute Lymphoblastic Leukemia : A Prospective, Single-Center, Single-Arm Clinical Trial

Unleashing the Power of CD19 CAR-T in Relapsed AML: Findings from a Prospective Single-Center Clinical Trial

Comparing the Efficacy and Safety of VAC (Venetoclax, Azacitidine, Chidamide) and VA Regimens As Induction Therapy for Newly Diagnosed Patients with Immunophenotypically Mature Monocytic AML

Bird Regimen Followed By Anti-BCMA CAR T-Cell Immunotherapy As First-Line Therapy for Newly Diagnosed Multiple Myeloma: A Prospective, Single-Arm, Phase 3 Trial

Safety and Efficacy of Blinatumomab and Auto-HSCT “Sandwich” Strategy As Consolidation Therapy for Ph Negative B Cell Acute Lymphoblastic Leukemia

VA Combined with Mbucy Conditioning Regimen Followed By Allo-HSCT Can Improve Survival of High-Risk AML Patients: A Prospective, Single-Center, Single-Arm Clinical Trial

Application of cfDNA-NGS Test in MRD Monitoring of Acute Leukemia Patients with CAR-T Cell Therapy

Venetoclax+Azacytidine Followed By Modified BuCy Conditioning Regimen for High Risk or Refractory/Relapsed Acute Lymphoblastic Leukemia and High Risk Myelodysplastic Syndromes

Rituximab Improves Clinical Outcomes of CAR-T Therapy for r/r B-ALL Via Sensitizing Leukemia Cells to CAR-T-Mediated Cytotoxicity and Reducing CAR-T Exhaustion

Efficacy and Safety of the Second CAR-T Therapy in Patients with Refractory/Relapsed Acute B-Cell Lymphoblastic Leukemia

Chidamide Combined with a Modified Bu-Cy Conditioning Regimen Improves Survival in Patients with T-Cell Acute Lymphoblastic Leukemia/Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Anti CD19 CART Therapy Following Allogenic Hematopoietic Stem Cell Transplantation Improved the Survival of Patients with BCR::ABL1 -like Acute Lymphoblastic Leukemia

Disruption of dNTP homeostasis by ribonucleotide reductase hyperactivation overcomes AML differentiation blockade

Tandem CD19/CD22 Dual Targets CAR T-Cells Bridging Hematopoietic Stem Cells Transplantation Acquires Robust Remission for Relapsed and Refractory B Acute Lymphoblastic Leukemia Patients

Tandem CD19/CD22 Dual Targets CAR-T Cells Therapy Obtains Superior CR Rate Than Single CD19 CAR-T Cells Infusion As Well As Sequential CD19 and CD22 CAR-T Cells Infusion for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Patients

Tandem CD19/CD22 Dual Targets CAR-T Cells Therapy Acquires Superior CR Rate Than CD19 CAR-T Cells: A Case Controlled Study

Repurposing Nelarabine to Induce Differentiation of Acute Myeloid Leukemia

CD38-Directed CAR-T Cell Therapy: A Novel Immunotherapy Strategy for Relapsed Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation

Tandem CAR T Cells Targeting CD19 and CD22 Is a Safe and Highly Efficacious Treatment for Relapse/ Refractory ALL Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only